niacinamide and xl765

niacinamide has been researched along with xl765 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Kuramoto, H; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Uehara, Y; Wada-Hiraike, O; Yano, T	1
Aoki, K; Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Makii, C; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Wada-Hiraike, O; Yano, T	1
Campana, F; Damstrup, L; Gandhi, L; Grande, E; Heist, RS; Hidalgo, M; Hyman, DM; Mita, MM; Schram, AM	1
Arend, RC; Birrer, MJ; Chimiczewski, P; Davis, AM; Ghamande, S; O'Malley, DM; Provencher, D; Vergote, I	1

Trials

2 trial(s) available for niacinamide and xl765

Article	Year
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. British journal of cancer, 2018, Volume: 119, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases	2018
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade Gynecologic oncology, 2020, Volume: 156, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult	2020

Article

Year

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.

British journal of cancer, 2018, Volume: 119, Issue:12

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2018

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade

Gynecologic oncology, 2020, Volume: 156, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult

2020

Other Studies

2 other study(ies) available for niacinamide and xl765

Article	Year
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. Gynecologic oncology, 2015, Volume: 138, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases	2015
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. Oncotarget, 2016, May-17, Volume: 7, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescence Resonance Energy Transfer; Humans; MAP Kinase Kinase Kinases; Models, Theoretical; Niacinamide; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases	2016

Article

Year

Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.

Gynecologic oncology, 2015, Volume: 138, Issue:2

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2015

Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.

Oncotarget, 2016, May-17, Volume: 7, Issue:20

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescence Resonance Energy Transfer; Humans; MAP Kinase Kinase Kinases; Models, Theoretical; Niacinamide; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2016